All patients
Age < 65y (younger) Age > 65y Asian type ECOG 0 ECOG 1 Gender, female Gender, male LDH > ULN LDH ≤ULN metastasis (brain) NO metastasis (brain) YES metastasis (liver ) PDL1 (CPS < 1) PDL1 (CPS >1) smoker (Current) smoker (Former) stage III (locally advanced) stage IV (metastatic)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
Extensive stage SCLC (Es-SCLC) - 1st Line (L1), anti-PD-(L)1 vs. placebo plus SoC, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results IMpower-133, 2018 0.70 [0.54; 0.91]
KEYNOTE-604, 2020 0.80 [0.65; 0.99]
0.76 [0.64 ; 0.89 ] IMpower-133, 2018, KEYNOTE-604, 2020 2 0% 856 low not evaluable deaths (OS) (extension)detailed results IMpower-133, 2018 0.76 [0.60; 0.96]
0.76 [0.60 ; 0.96 ] IMpower-133, 2018 1 0% 403 NA not evaluable PFS (extension)detailed results IMpower-133, 2018 0.77 [0.63; 0.95]
0.77 [0.63 ; 0.95 ] IMpower-133, 2018 1 0% 403 NA not evaluable progression or deaths (PFS)detailed results IMpower-133, 2018 0.77 [0.62; 0.96]
KEYNOTE-604, 2020 0.75 [0.61; 0.92]
0.76 [0.65 ; 0.88 ] IMpower-133, 2018, KEYNOTE-604, 2020 2 0% 856 low not evaluable objective responses (ORR)detailed results IMpower-133, 2018 0.84 [0.56; 1.25]
KEYNOTE-604, 2020 1.49 [1.01; 2.21]
1.12 [0.64 ; 1.97 ] IMpower-133, 2018, KEYNOTE-604, 2020 2 75% 856 low not evaluable objective responses (ORR) (extension)detailed results IMpower-133, 2018 0.84 [0.56; 1.25]
0.84 [0.56 ; 1.25 ] IMpower-133, 2018 1 0% 403 NA not evaluable AE (any grade)detailed results IMpower-133, 2018 14.63 [0.82; 259.59]
14.63 [0.82 ; 259.59 ] IMpower-133, 2018 1 0% 394 NA not evaluable AE (grade 3-4)detailed results IMpower-133, 2018 1.16 [0.77; 1.76]
KEYNOTE-604, 2020 1.12 [0.73; 1.73]
1.14 [0.85 ; 1.54 ] IMpower-133, 2018, KEYNOTE-604, 2020 2 0% 847 low not evaluable AE leading to death (grade 5)detailed results IMpower-133, 2018 0.35 [0.11; 1.11]
KEYNOTE-604, 2020 1.27 [0.56; 2.87]
0.71 [0.20 ; 2.53 ] IMpower-133, 2018, KEYNOTE-604, 2020 2 69% 847 low not evaluable AE leading to treatment discontinuation (any grade)detailed results IMpower-133, 2018 3.96 [1.57; 9.99]
KEYNOTE-604, 2020 2.64 [1.38; 5.07]
3.02 [1.77 ; 5.15 ] IMpower-133, 2018, KEYNOTE-604, 2020 2 0% 847 low not evaluable SAE (any grade)detailed results IMpower-133, 2018 1.12 [0.74; 1.70]
1.12 [0.74 ; 1.70 ] IMpower-133, 2018 1 0% 394 NA not evaluable STRAE (any grade)detailed results IMpower-133, 2018 1.26 [0.78; 2.06]
1.26 [0.78 ; 2.06 ] IMpower-133, 2018 1 0% 394 NA not evaluable TRAE (any grade)detailed results IMpower-133, 2018 1.56 [0.68; 3.56]
KEYNOTE-604, 2020 2.05 [0.69; 6.09]
1.72 [0.89 ; 3.32 ] IMpower-133, 2018, KEYNOTE-604, 2020 2 0% 840 low not evaluable TRAE (grade 3-4)detailed results IMpower-133, 2018 1.02 [0.68; 1.52]
KEYNOTE-604, 2020 1.12 [0.76; 1.65]
1.07 [0.81 ; 1.41 ] IMpower-133, 2018, KEYNOTE-604, 2020 2 0% 840 low not evaluable TRAE leading to death (grade 5)detailed results IMpower-133, 2018 0.99 [0.20; 4.96]
KEYNOTE-604, 2020 1.00 [0.32; 3.15]
1.00 [0.39 ; 2.54 ] IMpower-133, 2018, KEYNOTE-604, 2020 2 0% 840 low not evaluable Acute kidney injury TRAE (grade 3-4)detailed results IMpower-133, 2018 3.99 [0.18; 89.04]
3.99 [0.18 ; 89.04 ] IMpower-133, 2018 1 0% 394 NA not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results IMpower-133, 2018 0.99 [0.02; 50.14]
KEYNOTE-604, 2020 4.03 [0.18; 89.81]
2.35 [0.21 ; 26.79 ] IMpower-133, 2018, KEYNOTE-604, 2020 2 0% 840 low not evaluable Alopecia TRAE (grade 3-4)detailed results IMpower-133, 2018 0.99 [0.02; 50.14]
KEYNOTE-604, 2020 0.50 [0.02; 14.95]
0.67 [0.05 ; 8.74 ] IMpower-133, 2018, KEYNOTE-604, 2020 2 0% 840 low not evaluable Anaemia TRAE (grade 3-4)detailed results IMpower-133, 2018 1.18 [0.66; 2.12]
KEYNOTE-604, 2020 1.08 [0.63; 1.86]
1.13 [0.76 ; 1.68 ] IMpower-133, 2018, KEYNOTE-604, 2020 2 0% 840 low not evaluable Asthenia TRAE (grade 3-4)detailed results KEYNOTE-604, 2020 0.49 [0.12; 2.00]
0.49 [0.12 ; 2.00 ] KEYNOTE-604, 2020 1 0% 446 NA not evaluable Colitis TRAE (grade 3-4)detailed results IMpower-133, 2018 3.99 [0.18; 89.04]
KEYNOTE-604, 2020 0.50 [0.04; 5.53]
1.11 [0.15 ; 8.06 ] IMpower-133, 2018, KEYNOTE-604, 2020 2 7% 840 low not evaluable Constipation TRAE (grade 3-4)detailed results IMpower-133, 2018 1.98 [0.07; 59.51]
KEYNOTE-604, 2020 0.25 [0.01; 5.54]
0.64 [0.06 ; 6.33 ] IMpower-133, 2018, KEYNOTE-604, 2020 2 0% 840 low not evaluable Decreased appetite TRAE (grade 3-4)detailed results IMpower-133, 2018 3.99 [0.18; 89.04]
KEYNOTE-604, 2020 0.12 [0.01; 2.34]
0.68 [0.02 ; 20.43 ] IMpower-133, 2018, KEYNOTE-604, 2020 2 61% 840 low not evaluable Diabetes TRAE (grade 3-4)detailed results IMpower-133, 2018 0.99 [0.02; 50.14]
KEYNOTE-604, 2020 2.00 [0.07; 60.06]
1.48 [0.11 ; 19.35 ] IMpower-133, 2018, KEYNOTE-604, 2020 2 0% 840 low not evaluable Diarrhoea TRAE (grade 3-4)detailed results IMpower-133, 2018 4.02 [0.45; 36.30]
KEYNOTE-604, 2020 1.68 [0.40; 7.12]
2.19 [0.65 ; 7.31 ] IMpower-133, 2018, KEYNOTE-604, 2020 2 0% 840 low not evaluable Fatigue TRAE (grade 3-4)detailed results IMpower-133, 2018 3.00 [0.31; 29.09]
KEYNOTE-604, 2020 4.05 [0.45; 36.57]
3.50 [0.72 ; 17.02 ] IMpower-133, 2018, KEYNOTE-604, 2020 2 0% 840 low not evaluable Febrile neutropenia TRAE (grade 3-4)detailed results IMpower-133, 2018 0.48 [0.18; 1.30]
0.48 [0.18 ; 1.30 ] IMpower-133, 2018 1 0% 394 NA not evaluable Guillain-Barré syndrome TRAE (grade 3-4)detailed results IMpower-133, 2018 1.98 [0.07; 59.51]
1.98 [0.07 ; 59.51 ] IMpower-133, 2018 1 0% 394 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results IMpower-133, 2018 6.02 [0.30; 120.88]
KEYNOTE-604, 2020 6.07 [0.30; 121.85]
6.04 [0.72 ; 50.41 ] IMpower-133, 2018, KEYNOTE-604, 2020 2 0% 840 low not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results IMpower-133, 2018 0.99 [0.02; 50.14]
KEYNOTE-604, 2020 2.00 [0.07; 60.06]
1.48 [0.11 ; 19.35 ] IMpower-133, 2018, KEYNOTE-604, 2020 2 0% 840 low not evaluable Hypophysitis TRAE (grade 3-4)detailed results IMpower-133, 2018 0.99 [0.02; 50.14]
KEYNOTE-604, 2020 1.00 [0.02; 50.62]
0.99 [0.06 ; 15.96 ] IMpower-133, 2018, KEYNOTE-604, 2020 2 0% 840 low not evaluable Hypothyroidism TRAE (grade 3-4)detailed results IMpower-133, 2018 0.99 [0.02; 50.14]
KEYNOTE-604, 2020 1.00 [0.02; 50.62]
0.99 [0.06 ; 15.96 ] IMpower-133, 2018, KEYNOTE-604, 2020 2 0% 840 low not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results IMpower-133, 2018 4.02 [0.45; 36.30]
4.02 [0.45 ; 36.30 ] IMpower-133, 2018 1 0% 394 NA not evaluable Leucopenia TRAE (grade 3-4)detailed results IMpower-133, 2018 1.25 [0.48; 3.24]
KEYNOTE-604, 2020 1.27 [0.69; 2.33]
1.26 [0.76 ; 2.11 ] IMpower-133, 2018, KEYNOTE-604, 2020 2 0% 840 low not evaluable Myocarditis TRAE (grade 3-4)detailed results KEYNOTE-604, 2020 1.00 [0.02; 50.62]
1.00 [0.02 ; 50.62 ] KEYNOTE-604, 2020 1 0% 446 NA not evaluable Myositis TRAE (grade 3-4)detailed results KEYNOTE-604, 2020 2.00 [0.07; 60.06]
2.00 [0.07 ; 60.06 ] KEYNOTE-604, 2020 1 0% 446 NA not evaluable Nausea TRAE (grade 3-4)detailed results IMpower-133, 2018 0.99 [0.06; 15.94]
KEYNOTE-604, 2020 1.00 [0.14; 7.16]
1.00 [0.20 ; 4.97 ] IMpower-133, 2018, KEYNOTE-604, 2020 2 0% 840 low not evaluable Nephritis TRAE (grade 3-4)detailed results IMpower-133, 2018 1.98 [0.07; 59.51]
KEYNOTE-604, 2020 2.00 [0.07; 60.06]
1.99 [0.18 ; 22.08 ] IMpower-133, 2018, KEYNOTE-604, 2020 2 0% 840 low not evaluable Neutropenia TRAE (grade 3-4)detailed results IMpower-133, 2018 0.91 [0.57; 1.44]
KEYNOTE-604, 2020 1.04 [0.71; 1.51]
0.98 [0.73 ; 1.32 ] IMpower-133, 2018, KEYNOTE-604, 2020 2 0% 840 low not evaluable Pancreatitis TRAE (grade 3-4)detailed results IMpower-133, 2018 0.49 [0.04; 5.47]
KEYNOTE-604, 2020 2.00 [0.07; 60.06]
0.79 [0.11 ; 5.62 ] IMpower-133, 2018, KEYNOTE-604, 2020 2 0% 840 low not evaluable Pancytopenia TRAE (grade 3-4)detailed results IMpower-133, 2018 0.33 [0.03; 3.17]
0.33 [0.03 ; 3.17 ] IMpower-133, 2018 1 0% 394 NA not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results IMpower-133, 2018 3.99 [0.18; 89.04]
3.99 [0.18 ; 89.04 ] IMpower-133, 2018 1 0% 394 NA not evaluable Pneumonia TRAE (grade 3-4)detailed results IMpower-133, 2018 6.02 [0.30; 120.88]
6.02 [0.30 ; 120.88 ] IMpower-133, 2018 1 0% 394 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results IMpower-133, 2018 0.49 [0.04; 5.47]
KEYNOTE-604, 2020 6.07 [0.30; 121.85]
1.46 [0.13 ; 16.80 ] IMpower-133, 2018, KEYNOTE-604, 2020 2 39% 840 low not evaluable Rash TRAE (grade 3-4)detailed results IMpower-133, 2018 8.06 [0.42; 153.52]
8.06 [0.42 ; 153.52 ] IMpower-133, 2018 1 0% 394 NA not evaluable Severe skin reaction TRAE (grade 3-4)detailed results IMpower-133, 2018 0.99 [0.02; 50.14]
KEYNOTE-604, 2020 8.13 [0.43; 154.66]
3.81 [0.36 ; 40.15 ] IMpower-133, 2018, KEYNOTE-604, 2020 2 0% 840 low not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results IMpower-133, 2018 1.36 [0.67; 2.73]
KEYNOTE-604, 2020 1.18 [0.67; 2.09]
1.25 [0.80 ; 1.94 ] IMpower-133, 2018, KEYNOTE-604, 2020 2 0% 840 low not evaluable Uveitis TRAE (grade 3-4)detailed results KEYNOTE-604, 2020 2.00 [0.07; 60.06]
2.00 [0.07 ; 60.06 ] KEYNOTE-604, 2020 1 0% 446 NA not evaluable Vomiting TRAE (grade 3-4)detailed results IMpower-133, 2018 0.66 [0.11; 3.97]
KEYNOTE-604, 2020 0.66 [0.11; 4.01]
0.66 [0.18 ; 2.36 ] IMpower-133, 2018, KEYNOTE-604, 2020 2 0% 840 low not evaluable Alopecia AE (grade 3-4)detailed results KEYNOTE-604, 2020 0.50 [0.02; 14.95]
0.50 [0.02 ; 14.95 ] KEYNOTE-604, 2020 1 0% 446 NA not evaluable Anaemia AE (grade 3-4)detailed results KEYNOTE-604, 2020 1.03 [0.62; 1.73]
1.03 [0.62 ; 1.73 ] KEYNOTE-604, 2020 1 0% 446 NA not evaluable Asthenia AE (grade 3-4)detailed results KEYNOTE-604, 2020 0.72 [0.28; 1.82]
0.72 [0.28 ; 1.82 ] KEYNOTE-604, 2020 1 0% 446 NA not evaluable Back pain AE (grade 3-4)detailed results KEYNOTE-604, 2020 2.00 [0.07; 60.06]
2.00 [0.07 ; 60.06 ] KEYNOTE-604, 2020 1 0% 446 NA not evaluable Constipation AE (grade 3-4)detailed results KEYNOTE-604, 2020 0.50 [0.04; 5.53]
0.50 [0.04 ; 5.53 ] KEYNOTE-604, 2020 1 0% 446 NA not evaluable Cough AE (grade 3-4)detailed results KEYNOTE-604, 2020 0.50 [0.04; 5.53]
0.50 [0.04 ; 5.53 ] KEYNOTE-604, 2020 1 0% 446 NA not evaluable Decreased appetite AE (grade 3-4)detailed results KEYNOTE-604, 2020 0.25 [0.03; 2.22]
0.25 [0.03 ; 2.22 ] KEYNOTE-604, 2020 1 0% 446 NA not evaluable Diarrhoea AE (grade 3-4)detailed results KEYNOTE-604, 2020 1.00 [0.32; 3.15]
1.00 [0.32 ; 3.15 ] KEYNOTE-604, 2020 1 0% 446 NA not evaluable Dizziness AE (grade 3-4)detailed results KEYNOTE-604, 2020 1.00 [0.02; 50.62]
1.00 [0.02 ; 50.62 ] KEYNOTE-604, 2020 1 0% 446 NA not evaluable Dyspnoea AE (grade 3-4)detailed results KEYNOTE-604, 2020 0.75 [0.17; 3.37]
0.75 [0.17 ; 3.37 ] KEYNOTE-604, 2020 1 0% 446 NA not evaluable Fatigue AE (grade 3-4)detailed results KEYNOTE-604, 2020 1.51 [0.42; 5.44]
1.51 [0.42 ; 5.44 ] KEYNOTE-604, 2020 1 0% 446 NA not evaluable Headache AE (grade 3-4)detailed results KEYNOTE-604, 2020 0.50 [0.02; 14.95]
0.50 [0.02 ; 14.95 ] KEYNOTE-604, 2020 1 0% 446 NA not evaluable Hypothyroidism AE (grade 3-4)detailed results KEYNOTE-604, 2020 1.00 [0.02; 50.62]
1.00 [0.02 ; 50.62 ] KEYNOTE-604, 2020 1 0% 446 NA not evaluable Leucopenia AE (grade 3-4)detailed results KEYNOTE-604, 2020 1.27 [0.69; 2.33]
1.27 [0.69 ; 2.33 ] KEYNOTE-604, 2020 1 0% 446 NA not evaluable Nausea AE (grade 3-4)detailed results KEYNOTE-604, 2020 0.66 [0.11; 4.01]
0.66 [0.11 ; 4.01 ] KEYNOTE-604, 2020 1 0% 446 NA not evaluable Neutropenia AE (grade 3-4)detailed results KEYNOTE-604, 2020 1.12 [0.77; 1.63]
1.12 [0.77 ; 1.63 ] KEYNOTE-604, 2020 1 0% 446 NA not evaluable Peripheral oedema AE (grade 3-4)detailed results KEYNOTE-604, 2020 1.00 [0.02; 50.62]
1.00 [0.02 ; 50.62 ] KEYNOTE-604, 2020 1 0% 446 NA not evaluable Pneumonia AE (grade 3-4)detailed results KEYNOTE-604, 2020 1.54 [0.67; 3.50]
1.54 [0.67 ; 3.50 ] KEYNOTE-604, 2020 1 0% 446 NA not evaluable Pruritus AE (grade 3-4)detailed results KEYNOTE-604, 2020 1.00 [0.02; 50.62]
1.00 [0.02 ; 50.62 ] KEYNOTE-604, 2020 1 0% 446 NA not evaluable Pyrexia AE (grade 3-4)detailed results KEYNOTE-604, 2020 1.00 [0.06; 16.09]
1.00 [0.06 ; 16.09 ] KEYNOTE-604, 2020 1 0% 446 NA not evaluable Rash AE (grade 3-4)detailed results KEYNOTE-604, 2020 6.07 [0.30; 121.85]
6.07 [0.30 ; 121.85 ] KEYNOTE-604, 2020 1 0% 446 NA not evaluable Thrombocytopenia AE (grade 3-4)detailed results KEYNOTE-604, 2020 1.28 [0.73; 2.25]
1.28 [0.73 ; 2.25 ] KEYNOTE-604, 2020 1 0% 446 NA not evaluable Vomiting AE (grade 3-4)detailed results KEYNOTE-604, 2020 0.50 [0.09; 2.73]
0.50 [0.09 ; 2.73 ] KEYNOTE-604, 2020 1 0% 446 NA not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-07-02 13:22 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 162
- treatments: 367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,854,374,1073,953,672,1080,862,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258
